Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
220 hedge funds and large institutions have $3.33B invested in Global Blood Therapeutics, Inc. in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 81 increasing their positions, 71 reducing their positions, and 43 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 71
6% less funds holding
Funds holding: 234 → 220 (-14)
11% less call options, than puts
Call options by funds: $31.8M | Put options by funds: $35.8M
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
23% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 43
30% less capital invested
Capital invested by funds: $4.73B → $3.33B (-$1.4B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$210M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$104M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$66M |
| 4 |
RI
RTW Investments
New York
|
+$48.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$41.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$59.6M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$58M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$40.4M |
| 4 |
DM
Deerfield Management
New York
|
-$20M |
| 5 |
Millennium Management
New York
|
-$14.7M |
GBT Hedge Fund Activity: Q1 2020 in Review
220 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q1 2020, worth a combined $3.33B — down 30% from $4.73B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of GBT and 33 opened new positions — a net loss of 10 holders — while 71 trimmed existing stakes and 81 added.
The largest buyer was Fidelity Investments, adding an estimated $210M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $59.6M sold.
- 220 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q1 2020, down from 234 in Q4 2019.
- Funds reported $3.33B of Global Blood Therapeutics, Inc. stock for Q1 2020, down 30% quarter-over-quarter.
- 33 funds opened new Global Blood Therapeutics, Inc. positions in Q1 2020 and 43 closed out, a net change of -10 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q1 2020 was Fidelity Investments, an estimated $210M added.
- The largest Global Blood Therapeutics, Inc. seller in Q1 2020 was Farallon Capital Management, an estimated $59.6M sold.
Based on aggregated 13F filings for Q1 2020.